SPL Medical announces achievement of major Phase III clinical development milestone

SPL Medical announces achievement of major Phase III clinical development milestone

SPL medical has its proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached a major milestone by inclusion of more than 50 % of the planned patient group into this trial.

No Comments

Sorry, the comment form is closed at this time.